Merck and Moderna reported that their personalized mRNA neoantigen vaccine, intismeran autogene, met key goals in a phase 3 melanoma trial when combined with Keytruda in the adjuvant setting. The companies said the regimen significantly improved recurrence-free survival and distant metastasis-free survival at an interim analysis. The announcement adds a regulatory and scientific validation step for neoantigen vaccines, which have been viewed as promising but difficult to prove in randomized phase 3. The trial continues for additional endpoints such as overall survival, but the companies highlighted no new safety signals in the interim data. For biotech investors and developers, the update raises the odds that personalized mRNA cancer vaccines can move beyond proof-of-concept into a repeatable clinical approach—potentially reshaping how companies design next-generation individualized immunotherapies.